The Neo-Adjuvant Lapatinib and/or Trastuzumab Treatment Organisation (Neo-ALTTO) study is a randomised, multicentre open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer.
Coordinating groups: BrEAST / SOLTI
Study design
Start date: December 2007 Closure date: December 2009 Target nr. of patients: 450 Final accrual: 454
Reason for closure: reached target accrual